Mesenchymal stem cells attenuate vascular remodeling in monocrotaline-induced pulmonary hypertension rats

Abstract

Intravenous and intratracheal implantation of mesenchymal stem cells (MSCs) may offer ameliorating effects on pulmonary hypertension (PH) induced by monocrotaline (MCT) in rats. The aim of this study was to examine the anti-remodeling effect of intravenous MSCs (VMSCs) and intratracheal MSCs (TMSCs) in rats with PH, and the underlying mechanisms. MSCs were isolated from rat bone marrow and cultured. PH was induced in rats by intraperitoneal injection of MCT. One week after MCT administration, the rats were divided into 3 groups in terms of different treatments: VMSCs group (intravenous injection of MSCs), TMSCs group (intratracheal injection of MSCs), PH group (no treatment given). Those receiving saline instead of MCT served as negative control (control group). Pulmonary arterial structure was pathologically observed, pulmonary arterial dynamics measured, and remodeling-associated cytokines Smad2 and Smad3 detected in the lungs, three weeks after MCT injection. The results showed that PH group versus control group had higher pulmonary arterial pressure (PAP) and wall thickness index (WTI) 21 days after MCT treatment. The expression of phosphorylated (p)-Smad2 and the ratio of p-Smad2/Smad2 were much higher in PH group than in control group. Fluorescence-labeled MSCs were extensively distributed in rats’ lungs in VMSCs and TMSCs groups 3 and 14 days after transplantation, but not found in the media of the pulmonary artery. WTI and PAP were significantly lower in both VMSCs and TMSCs groups than in PH group three weeks after MCT injection. The p-Smad2 expression and the ratio of p-Smad2/Smad2 were obviously reduced in VMSCs and TMSCs groups as compared with those in PH group. In conclusion, both intravenous and intratracheal transplantation of MSCs can attenuate PAP and pulmonary artery remodeling in MCT-induced PH rats, which may be associated with the early suppression of Smad2 phosphorylation via paracrine pathways.

Keywords

mesenchymal stem cells / pulmonary hypertension / Smad2 / anti-remodeling

References

[1] BarteldsB., van LoonR.L., MohauptS., et al.. Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension. Chest, 2012, 141(3): 651-660

[2] XiongM., YaoJ.P., WuZ.K., et al.. Fibrosis of pulmonary vascular remodeling in carotid artery-jugular vein shunt pulmonary artery hypertension model of rats. Eur J Cardiothorac Surg, 2012, 41(1): 162-166

[3] UmarS., de VisserY.P., SteendijkP., et al.. Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension. Am J Physiol Heart Circ Physiol, 2009, 297(5): H1606-H1616

[4] TakemiyaK., KaiH., YasukawaH., et al.. Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats. Basic Res Cardiol, 2010, 105(3): 409-417

[5] LiangO.D., MitsialisS.A., ChangM.S., et al.. Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension. Stem Cells, 2011, 29(1): 99-107

[6] Kanki-HorimotoS., HorimotoH., MienoS., et al.. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxidesynthase improves right ventricular impairments caused by pulmonary hypertension. Circulation, 2006, 114(1suppl): I181-I185

[7] BaberS.R., DengW., MasterR.G., et al.. Intratracheal mesenchymal stem cell administration attenuates monocrotaline induced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol, 2007, 292(2): H1120-H1128

[8] GroveD.A., XuJ., JoodiR., et al.. Attenuation of early airway obstruction by mesenchymal stem cells in a murine model of heterotopic tracheal transplantation. J Heart Lung Transplant, 2011, 30(3): 341-350

[9] KimE.S., ChangY.S., ChoiS.J., et al.. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells attenuates Escherichia coli-induced acute lung injury in mice. Respir Res, 2011, 12(1): 108

[10] MoodleyY., IlancheranS., SamuelC., et al.. Human amnion epithelial cell transplantation abrogates lung fibrosis and augments repair. Am J Respir Crit Care Med, 2010, 182(5): 643-651

[11] van HaaftenT., ByrneR., BonnetS., et al.. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med, 2009, 180(11): 1131-1142

[12] KawabataM., MiyazonoK.. Signal transduction of the TGF-β superfamily by Smad proteins. J Biochem, 1999, 125(1): 9-16

[13] MaW., HanW., GreerP.A., et al.. Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. J Clin Invest, 2011, 121(11): 4548-4566

[14] WangT., HanS.X., ZhangS.F., et al.. Role of chymase in cigarette smoke-induced pulmonary artery remodeling and pulmonary hypertension in hamsters. Respir Res, 2010, 11(1): 36

[15] ThomasM., DocxC., HolmesA.M., et al.. Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. Am J Pathol, 2009, 174(2): 380-389

[16] RichterA., YeagerM.E., ZaimanA., et al.. Impaired transforming growth factor-β signaling in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med, 2004, 170(12): 1340-1348

[17] GrahamB.B., Mentink-KaneM.M., El-HaddadH., et al.. Schistosomiasis-induced experimental pulmonary hypertension. Am J Pathol, 2010, 177(3): 1549-1561

[18] LuQ., PatelB., HarringtonE.O., et al.. Transforming growth factor-beta1 causes pulmonary microvascular endothelial cell apoptosis via ALK5. Am J Physiol Lung Cell Mol Physiol, 2009, 296(5): L825-L838

[19] ZaimanA.L., PodowskiM., MedicherlaS., et al.. Role of the TGF-βeta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med, 2008, 177(8): 896-905

[20] ZakrzewiczA., KouriF.M., NejmanB., et al.. The transforming growth factor-beta/Smad2,3 signalling axis is impaired in experimental pulmonary hypertension. Eur Respir J, 2007, 29(6): 1094-1104

[21] LongL., CrosbyA., YangX., et al.. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation, 2009, 119(4): 566-576

[22] MassagueJ.. TGF-beta signal transduction. Annu Rev Biochem, 1998, 67: 753-791

[23] RamosM.F., LaméM.W., SegallH.J., et al.. Smad signaling in the rat model of monocrotaline pulmonary hypertension. Toxicol Pathol, 2008, 36(2): 311-320

[24] LuanY., ZhangZ.H., WeiD.E., et al.. Implantation of mesenchymal stem cells improves right ventricular impairments caused by experimental pulmonary hypertension. Am J Med Sci, 2012, 343(5): 402-406

[25] AngeliniA., CastellaniC., RavaraB., et al.. Stem-cell therapy in an experimental model of pulmonary hypertension and right heart failure: role of paracrine and neurohormonal milieu in the remodeling process. J Heart Lung Transplant, 2011, 30(11): 1281-1293

[26] RampinoT., GregoriniM., BedinoG., et al.. Mesenchymal stromal cells improve renal injury in anti-Thy 1 nephritis by modulating inflammatory cytokines and scatter factors. Clin Sci, 2011, 120(1): 25-36

[27] ZhaoF., ZhangY.F., LiuY.G., et al.. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. Transplant Proc, 2008, 40(5): 1700-1705

[28] MegalouA.J., GlavaC., OikonomidisD.L., et al.. Transforming growth factor-β inhibition attenuates pulmonary arterial hypertension in rats. Int J Clin Exp Med, 2010, 3(4): 332-340

[29] ChienM.H., BienM.Y., KuC.C., et al.. Systemic human orbital fat-derived stem/stromal cell transplantation ameliorates acute inflammation in lipopolysaccharide-induced acute lung injury. Crit Care Med, 2012, 40(4): 1245-1253

[30] YaoW., FirthA.L., SacksR.S., et al.. Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonaryhypertension. Am J Physiol Lung Cell Mol Physiol, 2009, 296(6): L870-L878

[31] StewartD.J., MeiS.H.. Cell-based therapies for lung vascular diseases: lessons for the future. Proc Am Thorac Soc, 2011, 8(6): 535-540

[32] DengW., BivalacquaT.J., ChampionH.C., et al.. Gene therapy techniques for the delivery of endothelial nitric oxide synthase to the lung for pulmonary hypertension. Methods Mol Biol, 2010, 610(3): 309-321